Rezafungin for suppressive therapy of Candida auris in a patient with a left ventricular assist device (LVAD)

Rezafungin is a promising new antifungal in the armamentarium of drugs for treatment of invasive candidiasis, notably <i>C. auris</i>. Though the patient did develop a breakthrough <i>C. auris</i> bloodstream infection while on rezafungin therapy, his infection was well-controlled for a little over 4 months, which prevented any <i>C. auris</i>-related hospital admissions during that time period. This case represents the first example of rezafungin being used for an LVAD-associated <i>C. auris</i> infection.